NCT04700787View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

April 4, 2022

Conditions
Urinary Tract InfectionsPyelonephritis AcuteIntraabdominal Infections
Interventions
DRUG

Sulopenem

sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2

Trial Locations (1)

63110

Medical Facility, St Louis

Sponsors
All Listed Sponsors
lead

Iterum Therapeutics, International Limited

INDUSTRY